Following several years of modest growth, a new study published in Health Affairs reports a record low health care spending increase of 3.6 percent in 2013. The last time the annual growth rate was any smaller, Dwight Eisenhower was President and a gallon of milk cost 49 cents. The year was 1960.
The study indicates that prescription drug expenditures across government and private payers rose 2.5 percent last year, in line with overall health care spending. At the same time, the share of dispensed generic prescriptions continued to increase, and 4 out of every 5 prescriptions is now filled with a generic.
These trends reinforce the differences between prescription drugs and the rest of the U.S. healthcare system. Unlike other healthcare sectors, the market for prescription medicines represents a delicate balance of innovation and affordability. This balance, often referred to as the prescription drug lifecycle, produces long-term savings as a result of the initial investments and research by innovator companies. This leads both to new medicines, and over time, to generics that consumers use at low cost for many years. With this built in cost-containment, the process supports patient access to affordable medicines as well as incentives for future innovation, bolsteringhope for tomorrow’s treatments and cures.
Get updates on this subject and/or other relevant issues here.
Holly Campbell Holly Campbell is former deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.